Analytical Data
-
Gene name
SPRL4A
- Application
-
Alternative Names
LEP8; LCE4A; Late Cornified Envelope 4A; Late envelope protein 8; Small proline-rich-like epidermal differentiation complex protein 4A
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5TA78
-
Expression Region
Met1~Cys99
-
Molecular Weight
16kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SPRL4A, or Sprouty-related protein 4A, is a member of the Sprouty family of proteins, which are known to function as negative regulators of receptor tyrosine kinase (RTK) signaling pathways. These pathways play crucial roles in various cellular processes, including proliferation, differentiation, and apoptosis. Dysregulation of RTK signaling is often linked to cancer progression, making the understanding of Sprouty proteins, particularly SPRL4A, significant in cancer biology. Initial studies suggest that SPRL4A may influence cellular responses to growth factors and impact oncogenic signaling networks. The investigation of SPRL4A as a recombinant protein has gained attention due to its potential implications in targeted therapies and precision medicine. Researchers aim to elucidate the structure-function relationships of SPRL4A, assess its role in modulating signaling cascades, and explore its interactions with other cellular components. Additionally, producing SPRL4A as a recombinant protein allows for detailed biochemical studies and potential therapeutic applications. Overall, the exploration of SPRL4A and its biological effects may provide new insights into the regulatory mechanisms of cell signaling and contribute to the development of innovative approaches in cancer treatment.
